Angelini's $4.1B Move Puts European Pharma on US Soil

Angelini Pharma's $4.1B acquisition of Catalyst expands rare disease access and signals a bold US market entry

2 Jun 2026

Fewer than 3,000 Americans live with Lambert-Eaton myasthenic syndrome. That is a small number by any measure, and yet it sits at the centre of a $4.1bn transaction that says something useful about where pharmaceutical ambition is headed.

On May 7th, Angelini Pharma, an Italian drugmaker, agreed to buy Catalyst Pharmaceuticals, a US specialist in rare diseases, for $31.50 per share in cash. The price represented a 28% premium to Catalyst's recent average. Both boards approved the deal unanimously. Regulatory clearance and a Catalyst shareholder vote stand between the parties and a Q3 2026 close.

What Angelini is buying is not just revenue. Catalyst's three approved therapies, Firdapse for Lambert-Eaton myasthenic syndrome, Agamree for Duchenne muscular dystrophy, and Fycompa for epilepsy, each serve patients with few alternatives. For Angelini, which has built its reputation in central nervous system drugs on the European side of the Atlantic, the deal provides something harder to replicate from scratch: a functioning US commercial operation.

The timing is not incidental. April brought BioMarin's close of Amicus for $4.8bn. Days before Angelini's announcement, Chiesi agreed to acquire KalVista for $1.9bn. Three European pharma groups, three US rare-disease targets, all within weeks of one another. The pattern reflects a shared conclusion: selling orphan drugs in America at scale requires infrastructure that takes years to build and can be bought faster than it can be grown.

For patients, the calculus is imperfect but not unfavourable. Well-capitalised acquirers tend to expand support programmes and deepen engagement with regulators. Whether that holds once integration pressures arrive is a different question, one that deal announcements rarely answer.

Rare disease M&A has acquired its own momentum. Angelini's move confirms it is not slowing.